Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
Attention deficit with hyperactivity disorder (ADHD) is a very common behavioral problem
during childhood. It is estimated that up to 80% of this disorder could be related to genetic
factors. The most common treatment for ADHD is psychostimulants. In this study, the
researchers investigate the effect of genetic variants in increasing the risk for behaviours
pertinent to ADHD or in modulating the response of these behaviours to methylphenidate.
Response to methylphenidate is evaluated through a double blind placebo controlled one week
study.